UBS raised the firm’s price target on Teva (TEVA) to $30 from $28 and keeps a Buy rating on the shares. Teva, one of the firm’s top picks for 2025, is a de-risked story from a fundamental perspective with an accelerating brand transition, the analyst tells investors in a research note. The firm expects Teva to announce the sale of the Active Pharmaceutical Ingredients unit with Q4 results next week, and is now modeling Austedo 2027 sales at $2.4B, with Uzedy 2030 sales at $529M.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- FDA adds boxed warning to Teva’s Copaxone for allergic reaction
- Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
- Teva price target raised to $30 from $23 at Piper Sandler
- Teva call volume above normal and directionally bullish
- Teva enters pact with Klinge Biopharma, Formycon to commercialize FYB203